Kakajan Komurov , PhD

Member, Cancer Biology and Neural Tumors Program

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-803-5122

Email kakajan.komurov@cchmc.org

Computational and experimental approaches to characterize targetable cancer vulnerabilities; oncogene-induced stress pathways in cancer therapy; the study of mechanisms, implications and therapeutic vulnerabilities imposed by the severe epigenetic defects in a subset of cancers

Visit the Komurov Lab.

Dr. Komurov focuses on computational and systems biology of cancer. His research interests are centered on integrating in silico, in vitro and in vivo analyses to model and target cancer cell vulnerabilities. Research in the Komurov lab also involves development of new computational tools, including methodology and software, for effective integration of large ‘omics and prior functional interaction datasets for knowledge-based data analyses.
PhD: The University of Texas Southwestern Medical Center, Dallas, TX.

View PubMed Publications

Adams AK, Bolanos LC, Dexheimer PJ, Karns RA, Aronow BJ, Komurov K, Jegga AG, Casper KA, Patil YJ, Wilson KM, Starczynowski DT, Wells SI. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival. Oncotarget. 2015 Oct 26.

Segura-Cabrera A, Singh N, Komurov K. An integrated network platform for contextual prioritization of drugs and pathways. Mol Biosyst. 2015 Oct 13;11(11):2850-9.

Singh N, Joshi R, Komurov K. HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive. Sci Signal. 2015 May 26;8(378):ra52.

Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. Cancer Res. 2014 Dec 1;74(23):7037-47.

Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Christie S, Chen X, Rao DS, Grimes HL, Komurov K, Weirauch MT, Cancelas JA, Maciejewski JP, Starczynowski DT. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network. Cell Rep. 2014 Sep 11;8(5):1328-38.

Kim HS, Mendiratta S, Kim J, Pecot CV, Larsen JE, Zubovych I, Seo BY, Kim J, Eskiocak B, Chung H, McMillan E, Wu S, De Brabander J, Komurov K, Toombs JE, Wei S, Peyton M, Williams N, Gazdar AF, Posner BA, Brekken RA, Sood AK, Deberardinis RJ, Roth MG, Minna JD, White MA. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013 Oct 24;155(3):552-66.

Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan;132(1):166-75.

Lane A, Segura-Cabrera A, Komurov K. A comparative survey of functional footprints of EGFR pathway mutations in human cancers. Oncogene. 2014 Oct 23;33(43):5078-89.

Ward SE, Kim HS, Komurov K, Mendiratta S, Tsai PL, Schmolke M, Satterly N, Manicassamy B, Forst CV, Roth MG, García-Sastre A, Blazewska KM, McKenna CE, Fontoura BM, White MA. Host modulators of H1N1 cytopathogenicity. PLoS One. 2012;7(8):e39284.

Komurov K, Tseng JT, Muller M, Seviour EG, Moss TJ, Yang L, Nagrath D, Ram PT. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol. 2012;8:596.

Modeling and targeting the hexosamine pathway in drug resistance. Principal Investigator. Susan G. Komen for the Cure. Aug 2013-Jul 2016. CCR13263034.

Exploiting proteotoxic stress in therapy-refractory HER2+ breast cancers. Principal Investigator. National Cancer Institute. Apr 2015-Mar 2020. 1R01CA193549-01.

Global Transcript Shortening in cancers. Principal Investigator. Cincinnati Children's Hospital Medical Center RIP award. Sep 2015-Aug 2016.